-
Modeling Best Practices of Medically Integrated Pharmacies to Improve Treatment Monitoring and Therapy Adherence in Patients With HR+/HER2- Breast Cancer
04 Feb 2026 05:09 GMT
… with HR+/HER2- metastatic breast cancer. Availability of cyclin-dependent kinase … breast cancer, accounting for approximately 70% of cases. Although most breast cancers … localized disease. Management of metastatic breast cancer involves a variety of …
-
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
03 Feb 2026 22:51 GMT
… ) for treatment of patients with metastatic TNBC without germline BRCA1… with HR-proficient ovarian or breast cancer. Our mechanistic characterization may contribute …
-
<![CDATA[Dato-DXd Earns Priority Review in Unresectable/Metastatic TNBC]]>
04 Feb 2026 00:24 GMT
… patients with unresectable or metastatic triple-negative breast cancer who are ineligible … for patients with metastatic triple-negative breast cancer who are not … locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom …
-
<![CDATA[Dato-DXd Granted Priority Review as First-Line Therapy for Metastatic Triple-Negative Breast Cancer]]>
03 Feb 2026 18:36 GMT
… with unresectable or metastatic triple-negative breast cancer (TNBC) who … recurrent inoperable or metastatic TNBC who were … need in patients with metastatic TNBC. TROP2 is … recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. …
-
<![CDATA[FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC]]>
03 Feb 2026 22:45 GMT
… with unresectable or metastatic triple-negative breast cancer (TNBC). The … 15% of all breast cancer cases.1 While … for patients with metastatic triple-negative breast cancer who are … in first-line metastatic triple-negative breast cancer: Results from …
-
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
03 Feb 2026 15:44 GMT
…
Unresectable or Metastatic Breast Cancer
In the pooled …
While some breast cancers may test … breast cancer, an aggressive form of breast cancer, … breast-cancer. Accessed January 2026.
National Breast Cancer Foundation, Inc. Triple Negative Breast Cancer …
-
Nursing Interventions for Symptom Management in Breast Cancer: A Systematic Review
03 Feb 2026 15:28 GMT
… stage (whether early-stage or metastatic), patient age, type of ongoing … Neoplasms”[Mesh] OR breast cancer OR breast neoplasms OR breast tumor*) AND (symptom management … levels, and can even reduce metastasis recurrence rates.17
Domain III …
-
Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
03 Feb 2026 14:29 GMT
… in patients with metastatic triple-negative breast cancer for whom immunotherapy … trials of Datroway in breast cancer.
Additional regulatory submissions … 10,11
While some breast cancers may test positive … and absence of common breast cancer receptors, TNBC is …
-
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
03 Feb 2026 12:00 GMT
… locally advanced or metastatic breast cancer following recurrence or … evaluated in multiple metastatic breast cancer studies and … ) breast cancer is the most common subtype of breast cancer. … HR+/HER2- metastatic breast cancer. Zovegalisib is also …
-
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
03 Feb 2026 08:14 GMT
… in patients with metastatic triple negative breast cancer for whom … .
About Triple Negative Breast Cancer
TNBC accounts for approximately … 8,9
While some breast cancers may test positive … patients.
Unresectable or Metastatic Breast Cancer
In the pooled safety …
About
© 1995-2026